Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study

Patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) are insensitive to conventional chemotherapy and, therefore, have a poor prognosis. To evaluate the clinical efficacy and safety of low-dose decitabine in combination with small-dose CAG regimen (D-CAG regimen) in tre...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jing Liu, Xiaohong Liu, Jinsong Jia, Lizhong Gong, Shengye Lu, Jing Wang, Xiao-jun Huang, Hao Jiang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2022-01-01
Colecção:	Leukemia Research Reports
Assuntos:	Decitabine CAG regimen D-CAG regimen AML-MRC
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2213048922000668
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!